JNJ

238.34

-0.13%↓

UNH

275.18

+0.24%↑

TMO

547.45

+1.67%↑

ABT

111.8

+1.4%↑

ISRG

498.29

+2.04%↑

JNJ

238.34

-0.13%↓

UNH

275.18

+0.24%↑

TMO

547.45

+1.67%↑

ABT

111.8

+1.4%↑

ISRG

498.29

+2.04%↑

JNJ

238.34

-0.13%↓

UNH

275.18

+0.24%↑

TMO

547.45

+1.67%↑

ABT

111.8

+1.4%↑

ISRG

498.29

+2.04%↑

JNJ

238.34

-0.13%↓

UNH

275.18

+0.24%↑

TMO

547.45

+1.67%↑

ABT

111.8

+1.4%↑

ISRG

498.29

+2.04%↑

JNJ

238.34

-0.13%↓

UNH

275.18

+0.24%↑

TMO

547.45

+1.67%↑

ABT

111.8

+1.4%↑

ISRG

498.29

+2.04%↑

Kodu・Aktsiate loetelu・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Avatud

1.18 5.36

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.12

Max

1.17

Põhinäitajad
By Trading Economics
Sissetulek	17M -26M
Töötajad	171
EBITDA	19M -23M

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	26. veebr 2026

Turustatistika
By TradingEconomics
Turukapital	-29M 73M
Eelmine avamishind	-4.18
Eelmine sulgemishind	1.18

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

1.43 / 1.6 Toetus ja vastupanu

Pliant Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

9. veebr 2026, 17:25 UTC

Omandamised, ülevõtmised, äriostud

Eli Lilly to Buy Biotech Orna Therapeutics for Up to $2.4 Billion -- Update

9. veebr 2026, 23:46 UTC

Market Talk

Nikkei May Rise on Hopes for Domestic Policy Measures -- Market Talk

9. veebr 2026, 23:43 UTC

Market Talk

Gold Falls on Possible Technical Correction -- Market Talk

9. veebr 2026, 23:14 UTC

Market Talk

WiseTech's Bull Reckons AI-Driven Selloff Is Overdone -- Market Talk

9. veebr 2026, 22:29 UTC

Market Talk

Australian Coking Coal Price Seen Falling Once Supply Disruptions Ease -- Market Talk

9. veebr 2026, 22:19 UTC

Market Talk

Pro Medicus's Business Case Made More Compelling by AI Adoption -- Market Talk

9. veebr 2026, 22:08 UTC

Market Talk

Minerals 260 Bull Bets on Production Scale, Takeover Appeal -- Market Talk

9. veebr 2026, 22:01 UTC

Tulu

Friedman Industries Sees 4Q Sales Volume to Generally Consistent With 3Q, With Sequential Improvement in Sales Margins

9. veebr 2026, 21:59 UTC

Tulu

Friedman Industries: Hedging Activities Continued to Perform as Anticipated by Mitigating Impact of Commodity Price Volatility

9. veebr 2026, 21:59 UTC

Tulu

Friedman Industries: Average Selling Prices Began to Improve as Quarter Progressed

9. veebr 2026, 21:58 UTC

Tulu

Friedman Industries 3Q Sales $168M >FRD

9. veebr 2026, 21:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Financial Services Roundup: Market Talk

9. veebr 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. veebr 2026, 21:48 UTC

Tulu

Friedman Industries 3Q EPS 43c >FRD

9. veebr 2026, 21:17 UTC

Tulu

Kyndryl Stock Drops 55%. It's So Much Worse Than an Earnings Miss. -- Barrons.com

9. veebr 2026, 21:13 UTC

Market Talk

U.S. Ethanol Crush Margins Near Break-Even -- Market Talk

9. veebr 2026, 21:04 UTC

Tulu

Retail Sales Data Should Confirm a Robust Holiday Season -- Barrons.com

9. veebr 2026, 20:30 UTC

Market Talk

Oil Futures Gain As U.S.-Iran Risk Premium Holds -- Market Talk

9. veebr 2026, 20:02 UTC

Market Talk

U.S. Natural Gas Falls on Warmer Weather Outlook -- Market Talk

9. veebr 2026, 19:42 UTC

Market Talk

Japan's Yield Curve Expected to Flatten -- Market Talk

9. veebr 2026, 19:31 UTC

Market Talk

Nike Seen Regaining Relevance With Consumers -- Market Talk

9. veebr 2026, 19:27 UTC

Market Talk

Gold Climbs Back Over $5,000/oz -- Market Talk

9. veebr 2026, 19:05 UTC

Market Talk

Nike Returns to List of Hottest Brands -- Market Talk

9. veebr 2026, 18:19 UTC

Market Talk

Lower Dollar Doesn't Translate to Boost in Grains -- Market Talk

9. veebr 2026, 17:41 UTC

Tulu

Omandamised, ülevõtmised, äriostud

These Stocks Are Today's Movers: Kyndryl, Hims & Hers, Novo Nordisk, AppLovin, Monday.com, Valaris, and More -- Barrons.com

9. veebr 2026, 17:31 UTC

Tulu

Omandamised, ülevõtmised, äriostud

These Stocks Are Today's Movers: Kyndryl, Hims & Hers, Novo Nordisk, Monday.com, Valaris, Cleveland-Cliffs, and More -- Barrons.com

9. veebr 2026, 17:20 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Financial Services Roundup: Market Talk

9. veebr 2026, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. veebr 2026, 17:17 UTC

Market Talk

Century Aluminum Announces Next Steps of Okla. Project -- Market Talk

9. veebr 2026, 17:16 UTC

Tulu

Kyndryl Stock Drops 56%. It's So Much Worse Than an Earnings Miss. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Pliant Therapeutics Inc Prognoos

Hinnangu Konsensus

By TipRanks

Müü

1 ratings

Osta

Hoia

Müü

Põhineb 1 analüütiku instrumendi Pliant Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.43 / 1.6Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.